Tandem Diabetes Care/$TNDM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tandem Diabetes Care
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Ticker
$TNDM
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
2,650
ISIN
US8753722037
Website
TNDM Metrics
BasicAdvanced
$1.4B
-
-$2.80
1.53
-
Price and volume
Market cap
$1.4B
Beta
1.53
52-week high
$48.24
52-week low
$15.75
Average daily volume
1.4M
Financial strength
Current ratio
2.302
Quick ratio
1.718
Long term debt to equity
281.182
Total debt to equity
320.752
Interest coverage (TTM)
-12.46%
Profitability
EBITDA (TTM)
-75.068
Gross margin (TTM)
52.22%
Net profit margin (TTM)
-18.71%
Operating margin (TTM)
-9.35%
Effective tax rate (TTM)
-5.41%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-6.17%
Return on equity (TTM)
-92.31%
Valuation
Price to revenue (TTM)
1.364
Price to book
8.75
Price to tangible book (TTM)
8.75
Price to free cash flow (TTM)
-353.278
Free cash flow yield (TTM)
-0.28%
Free cash flow per share (TTM)
-5.78%
Growth
Revenue change (TTM)
27.65%
Earnings per share change (TTM)
28.88%
3-year revenue growth (CAGR)
10.04%
10-year revenue growth (CAGR)
33.67%
3-year earnings per share growth (CAGR)
215.35%
10-year earnings per share growth (CAGR)
-21.85%
What the Analysts think about TNDM
Analyst ratings (Buy, Hold, Sell) for Tandem Diabetes Care stock.
Bulls say / Bears say
Tandem Diabetes Care's recent launch of the t:slim X2 insulin pump with Control-IQ technology has been well-received, potentially driving increased sales and market share. (bloomberg.com)
The company's strategic partnership with Dexcom to integrate continuous glucose monitoring systems enhances product offerings and could lead to higher adoption rates. (reuters.com)
Tandem's expansion into international markets, including recent approvals in Europe and Asia, positions the company for significant revenue growth. (seekingalpha.com)
Increased competition from larger medical device companies entering the insulin pump market could pressure Tandem's market share and pricing power. (bloomberg.com)
Supply chain disruptions have led to delays in product shipments, potentially impacting quarterly revenues and customer satisfaction. (reuters.com)
Regulatory challenges in obtaining approvals for new products in certain international markets may hinder Tandem's expansion plans. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TNDM Financial Performance
Revenues and expenses
TNDM Earnings Performance
Company profitability
TNDM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tandem Diabetes Care stock?
Tandem Diabetes Care (TNDM) has a market cap of $1.4B as of June 20, 2025.
What is the P/E ratio for Tandem Diabetes Care stock?
The price to earnings (P/E) ratio for Tandem Diabetes Care (TNDM) stock is 0 as of June 20, 2025.
Does Tandem Diabetes Care stock pay dividends?
No, Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Tandem Diabetes Care dividend payment date?
Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders.
What is the beta indicator for Tandem Diabetes Care?
Tandem Diabetes Care (TNDM) has a beta rating of 1.53. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.